The Senate Judiciary Committee has scheduled a vote for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; the FDA is targeting websites illegally marketing and selling opioids; and the White House has dropped its proposal to cut Ebola funding amid the outbreak in Congo.
Senate Panel Schedules a Vote on CREATES Act Bill
On Tuesday, the Senate Judiciary Committee announced that it’s moving forward on the drug pricing bill known as the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, The Hill reported. The bill would crack down on drug companies attempting to delay the cheaper generic drugs from entering the market. Senator Chuck Grassley, R-Iowa, has scheduled the vote for Thursday. Voting on the bill has been at a standstill for months amid opposition from pharmaceutical companies, despite bipartisan support of the bill.
FDA Targets Websites Marketing Opioids Illegally
Early Tuesday morning, the FDA outlined a framework for cracking down on illegal opioid sales on the internet. According to STAT news, just hours later, FDA Commissioner Scott Gottlieb, MD, came out with a list of 9 operators of 53 websites that the FDA had sent formal warnings to for engaging in illegal marketing and sales of opioids. The agency warned that companies failing to address violations outlined in the warning letters could have their products seized or face other legal actions.
White House Drops Plan to Cut Ebola Spending
Amid the Ebola outbreak in Congo, the White House has dropped a proposal to cut $252 million in leftover funding to fight the virus in Africa, AP news reported. The proposed cut to Ebola funding was unveiled last month in the wake of the $1.3 trillion spending bill. As of late May, the outbreak was believed to have killed at least 27 people.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More